FDA Approves Belzutifan Plus Lenvatinib After PD 1 Therapy
FDA approved oral belzutifan plus lenvatinib for advanced clear-cell RCC after PD-1 or PD-L1 therapy. In the 747-patient randomized Phase 3 LITESPARK-011 study, the combination reduced the risk of progression or death by 26%…
